Finally, the development of a delivery system for AHR agonists and autoantigens will be urgent because successful delivery of such contents to DCs and other myeloid cells and subsequent establishment of tolerance will increase the use of therapeutic vaccines for autoimmune diseases. Here, AHR is linked to autoimmune disease.